Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227586 | 0.80 | HTR2C (0.49) | HTR2CTNKSTNKS2PARP1HTR2A | |
| SCHEMBL7162498 | 0.77 | PARP1 (0.37) | CHRM3PARP1 | |
| SCHEMBL31351621 | 0.71 | HTR2C (0.63) | HTR2CTNKSTNKS2HTR2AHTR2B | |
| SCHEMBL25431342 | 0.71 | HPGD (0.41) | HTR2CTNKSTNKS2CHRM3PARP1 | |
| SCHEMBL23972783 | 0.69 | HTR2C (0.56) | HTR2CTNKSTNKS2PARP1 | |
| SCHEMBL5228377 | 0.68 | HTR2C (0.49) | HTR2CTNKSTNKS2PARP1HTR2B | |
| SCHEMBL14344503 | 0.65 | MTHFD2 (0.49) | HTR2CTNKSTNKS2PARP1HTR2A | |
| SCHEMBL9232984 | 0.65 | ALDH1A1 (0.32) | NPSR1 | |
| SCHEMBL23973135 | 0.62 | HTR2C (0.51) | HTR2CTNKSTNKS2PARP1HTR2A | |
| SCHEMBL23972240 | 0.61 | TNKS (0.47) | HTR2CTNKSTNKS2PARP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |